ArticlePsychiatry and clinical neurosciences2026
Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation.
Article in Psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Response to [Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia].Psychiatry and clinical neurosciences · 2026Article
- Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia.Psychiatry and clinical neurosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
aimVesicular monoamine transporter 2 (VMAT2) inhibitors have been approved for the treatment of tardive dyskinesia (TD), whereas anticholinergic agents are still widely used for this condition. This study aimed to compare the risk of major clinical adverse outcomes among patients with TD treated with VMAT2 inhibitors versus anticholinergic agents.
methodsThis retrospective cohort study used the TriNetX collaborative network, which aggregates de-identified electronic health records (EHRs) across the United States. Adults aged≧18 years with TD who initiated anticholinergic agents or VMAT2 inhibitors for the first time between 2019 and 2025 were included. We applied a target trial emulation framework under the intention-to-treat principle. 1:1 propensity score matching was applied. Cox hazard regression was used to assess the primary outcomes: incident fall, injury, fracture, and mortality, and secondary outcomes: incident delirium, dementia, and arrythmia.
resultsAfter propensity score matching, 2749 patients (mean age: 59 years; 34% male) were included in each treatment group with well-balanced demographics. Compared with anticholinergic therapy, VMAT2 inhibitors were associated with significantly lower risks of fall (HR = 0.83, 95% CI = 0.73-0.93), injury (HR = 0.77, 95% CI = 0.71-0.85), fracture (HR = 0.82, 95 % CI = 0.72-0.94), and mortality (HR = 0.71, 95% CI = 0.58-0.87). Secondary outcomes also favored VMAT2 inhibitors, with reduced risks of delirium (HR = 0.39, 95% CI = 0.29-0.52), dementia (HR = 0.55, 95 % CI = 0.45-0.69), and arrhythmia (HR = 0.72, 95% CI = 0.60-0.85).
conclusionThis real-world study suggests that VMAT2 inhibitors may offer a safer therapeutic option than anticholinergic agents for TD management, supporting their potential clinical advantage and the need for further long-term validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.